Search has long been one of the clearest signals of patient and provider intent. But the search experience itself is changing.

AI-generated answers, zero-click search behavior, and conversational discovery tools are increasingly shaping how people access health information. Patients may find answers without ever visiting a brand site. HCPs may use AI tools to summarize scientific information, explore clinical questions, or navigate a crowded content landscape.

That does not make search less important. It makes the surrounding intent signals more important.

Healthcare marketers need to think beyond traditional search rankings and clicks. The opportunity is to understand what people are trying to solve, what content environments they are engaging with, and how media can reach them when intent is active, even if the journey does not look like a classic search-to-site visit.

The HCP media landscape is becoming more crowded, more specialized, and more competitive. New media players are entering the market with different data assets, audience models, engagement formats, and performance promises. At the same time, older assumptions about how to reach and measure HCPs are being challenged.

Paid search is one example. For years, it has been treated as a reliable bottom-funnel tactic, but its limitations are becoming more visible. Costs are high, competition is intense, and the signal is often narrower than marketers need. Search can capture declared intent, but it does not always reveal the broader research journey, the clinical context, or the educational moments that happen before a query is typed.

Deterministic HCP targeting also remains a challenge. Even when marketers have strong identity data, a significant portion of digital audiences may be difficult or impossible to identify with confidence. That creates a practical issue: if only part of the addressable audience can be deterministically matched, campaigns need a strategy for engaging the rest without sacrificing relevance, compliance discipline, or measurement quality.

This is where the market is moving beyond one-size-fits-all HCP targeting. The next phase requires a more flexible model: verified HCP reach where available, contextual relevance where identity is limited, and intent-based signals that help marketers understand professional interest without depending on a single source of truth.

For pharma marketers, the question is no longer simply, “Can we target HCPs?” It is, “Can we reach the right HCPs, in the right mindset, with enough confidence to optimize performance responsibly?”

For years, omnichannel marketing has often meant coordinating messages across email, media, field teams, websites, and other touchpoints. That coordination still matters, but the expectation is evolving.

The next stage is more dynamic. Marketers want campaigns that can respond to real behavior, not just pre-set journeys. They want media that can inform the broader engagement strategy, not sit off to the side as an awareness tactic.

This is especially important in pharma, where audience quality, timing, compliance, and measurement all have to work together. The strongest media strategies will be those that connect campaign activity to meaningful signals: condition interest, content engagement, HCP specialty, patient journey stage, and measurable downstream action.
At mid-year, marketers should ask whether their media plans are simply running across channels, or whether those channels are actually learning from one another.

Privacy is no longer a constraint to work around at the end of a campaign. It is part of the foundation.

As cookies, identifiers, platform policies, and state-level privacy rules continue to evolve, healthcare marketers need dependable ways to understand audiences, activate campaigns, and measure performance in a privacy-safe manner. But the conversation is no longer just about whether an identifier works. It is about whether the data was collected with appropriate consent, whether the activation is transparent, and whether the measurement approach can withstand scrutiny.

That scrutiny is increasing. Pixel use, website tracking, and third-party data sharing have all come under greater legal and regulatory attention, particularly in healthcare contexts where consumer behavior may imply sensitive health interests. For pharma brands, this creates a real attribution challenge. Marketers still need to understand what is working, but they also need to avoid measurement practices that create unnecessary risk.

The key question is not just, “Can we attribute this conversion?” It is, “Can we measure performance in a way that respects consent, minimizes sensitive data exposure, and aligns with the expectations of patients, providers, regulators, and brand teams?”

This is pushing the industry toward cleaner identity infrastructure, stronger consent frameworks, more thoughtful use of first-party and deterministic data, and measurement models that do not rely on indiscriminate tracking. For both DTC and HCP campaigns, privacy-safe identity is becoming less of a technical detail and more of a strategic requirement.

The brands that adapt fastest will be those that can balance performance with responsibility: reducing waste, improving audience confidence, and measuring outcomes without overreaching.

Contextual targeting has often been discussed as an alternative to cookies. But in healthcare media, its value is broader than that.

The environment where a message appears matters. A campaign seen alongside relevant, credible health content carries a different weight than the same message delivered in a generic or poorly matched environment. For patients, context can align with an active information need. For HCPs, it can reflect professional relevance and clinical interest.
This is why contextual media is having a renewed moment. It helps marketers align message, mindset, and environment. It can also support privacy-safe activation by focusing on what content people are engaging with, rather than relying only on personal identifiers.

For pharma marketers navigating AI disruption, privacy expectations, attribution concerns, and fragmented HCP journeys, context offers something valuable: a way to meet people where their attention and intent are already present.

The common thread across these trends is not simply “more technology.” It is better signal quality.

Healthcare marketers need to know who they are reaching, what mindset they are reaching them in, what consent and privacy considerations apply, and how engagement connects to measurable action. That requires a media strategy built around high-intent moments, trusted environments, clean identity, responsible attribution, and flexible measurement.

As teams plan for the second half of 2026, the most important question may not be whether they are doing enough media. It may be whether their media is close enough to the moments that matter.

For pharma brands, the opportunity is clear: recalibrate around intent, context, identity, consent, and trust, and build campaigns that reflect how patients and HCPs are actually engaging today.